Jazz Pharmaceuticals plc (J7Z.F)
| Previous close | 95.76 |
| Open | 95.88 |
| Bid | 92.92 x 1700 |
| Ask | 93.48 x 1700 |
| Day's range | 93.16 - 95.98 |
| 52-week range | 93.16 - 134.35 |
| Volume | |
| Avg. volume | 28 |
| Market cap | 5.908B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 20.89 |
| EPS (TTM) | 4.46 |
| Earnings date | 06 Aug 2024 - 14 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 208.50 |
Insider MonkeyIs Jazz Pharmaceuticals plc (JAZZ) the Best Pot Stock to Buy Now?
We recently compiled a list of the 8 Best Pot Stocks to Buy. In this article, we are going to take a look at where Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands against the other pot stocks. The history of the cannabis industry is riddled with changes and conflicting legislation. The international media has played an important […]
Investor's Business DailyJazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure
Jazz stock toppled Thursday — but shares of key rival Praxis surged — after its essential tremor drug failed in midstage testing.
PR NewswireJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET). Suvecaltamide did not achieve statistical significance at 30mg versus placebo on the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessmen
